GSK plc
GSK
$40.56
$0.511.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.26% | 9.08% | 12.16% | 10.31% | 4.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.26% | 9.08% | 12.16% | 10.31% | 4.16% |
| Cost of Revenue | 8.40% | 2.62% | 3.09% | -2.04% | -13.56% |
| Gross Profit | 5.44% | 11.77% | 15.97% | 15.79% | 13.00% |
| SG&A Expenses | 21.18% | 24.53% | 9.68% | 11.74% | 12.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 68.84% | 19.33% | -42.69% | -113.06% | -99.62% |
| Total Operating Expenses | 18.42% | 15.09% | 7.27% | 4.41% | -1.15% |
| Operating Income | -25.50% | -8.18% | 26.70% | 28.64% | 21.11% |
| Income Before Tax | -41.54% | -53.70% | -19.76% | 6.13% | 7.16% |
| Income Tax Expenses | -29.09% | -41.58% | -2.56% | 19.15% | 4.73% |
| Earnings from Continuing Operations | -43.32% | -55.15% | -22.00% | 4.32% | 7.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.16% | 23.08% | 27.41% | 12.18% | 20.14% |
| Net Income | -46.81% | -57.52% | -72.22% | -67.46% | -65.88% |
| EBIT | -25.50% | -8.18% | 26.70% | 28.64% | 21.11% |
| EBITDA | -12.54% | -2.82% | 16.05% | 9.50% | 6.89% |
| EPS Basic | -47.12% | -57.78% | -72.43% | -67.67% | -66.07% |
| Normalized Basic EPS | -29.08% | -6.20% | 36.48% | 37.23% | 31.48% |
| EPS Diluted | -47.11% | -57.72% | -72.39% | -67.61% | -65.98% |
| Normalized Diluted EPS | -29.02% | -6.18% | 36.42% | 37.19% | 31.50% |
| Average Basic Shares Outstanding | 0.62% | 0.61% | 0.61% | 0.62% | 0.64% |
| Average Diluted Shares Outstanding | 0.70% | 0.68% | 0.65% | 0.65% | 0.59% |
| Dividend Per Share | 8.08% | 13.06% | 12.98% | 6.28% | -5.40% |
| Payout Ratio | 1.10% | 1.51% | 2.60% | 1.34% | 0.89% |
